Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci
- 18 November 2021
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 59 (12)
- https://doi.org/10.1128/jcm.01635-21
Abstract
Clinical isolates of Enterobacterales other than Escherichia coli (EOTEC), non-fermenting Gram-negative bacilli, and Gram-positive cocci were tested for susceptibility to fosfomycin using Etest® and reference agar dilution. Applying EUCAST (v. 11.0, 2021) intravenous fosfomycin breakpoints, Etest® MICs for EOTEC showed essential agreement (EA), categorical agreement (CA), major error (ME), and very major error (VME) rates of 70.4%, 88.4%, 4.1%, and 32.1%, respectively. No species of EOTEC tested with acceptable rates for all of EA (≥90%), CA (≥90%), ME (≤3%), and VME (≤3%). Etest® MICs for Enterococcus faecalis, interpreted using CLSI oral/urine criteria (M100, 2021), showed EA, CA, minor error, ME, and VME rates of 98.5%, 81.2%, 18.8%, 0%, and 0%. Against Staphylococcus aureus, EA, CA, and ME rates were 84.1%, 98.7%, and 1.3% (EUCAST intravenous criteria). S. aureus isolates with fosfomycin MICs >32 μg/ml (resistant) were not identified by agar dilution. We conclude performing fosfomycin Etest® on isolates of S. aureus will reliably identify fosfomycin-susceptible isolates with low, acceptable rates of MEs and VMEs. Testing of urinary isolates of E. faecalis by Etest® is associated with an unacceptably high rate of minor errors (18.8%) but low, acceptable rates of MEs and VMEs when results are interpreted using CLSI criteria. Isolates of EOTEC tested by Etest® with resulting MICs interpreted by EUCAST criteria were associated with an unacceptably high VME rate (32.1%). In vitro testing of clinical isolates beyond E. coli, E. faecalis, and S. aureus to determine susceptibility to fosfomycin is problematic with current methods and breakpoints.Keywords
Funding Information
- Verity Pharmaceuticals
This publication has 13 references indexed in Scilit:
- 42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance studyJournal of Antimicrobial Chemotherapy, 2019
- Activity of fosfomycin when tested against US contemporary bacterial isolatesDiagnostic Microbiology and Infectious Disease, 2018
- Discrepancies in fosfomycin susceptibility testing of KPC-producing Klebsiella pneumoniae with various commercial methodsDiagnostic Microbiology and Infectious Disease, 2018
- Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusionJournal of Antimicrobial Chemotherapy, 2018
- Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreementInternational Journal of Antimicrobial Agents, 2018
- Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in CanadaCanadian Journal of Infectious Diseases and Medical Microbiology, 2018
- Frequency and Mechanisms of Spontaneous Fosfomycin Nonsusceptibility Observed upon Disk Diffusion Testing of Escherichia coliJournal of Clinical Microbiology, 2018
- Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolatesInternational Journal of Antimicrobial Agents, 2015
- Susceptibility of Multiresistant Gram-Negative Bacteria to Fosfomycin and Performance of Different Susceptibility Testing MethodsAntimicrobial Agents and Chemotherapy, 2014
- Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalisfrom ten North American medical centres by three methodsJournal of Antimicrobial Chemotherapy, 1999